The GoodRx 2019 End-of-Year Report
This year, frustrations over the high cost of prescription drugs continued to sweep the nation. New affordable medications became available, but the first $2 million drug was also approved. And while prescription drug prices were a problem in 2019, the healthcare system as a whole also remained fragmented and confusing for many Americans.
Our team here at GoodRx believes that drug price transparency can lead to lower medication costs and improved healthcare. Better price visibility can affect how prices are set and help inform patients so that they make better decisions at the pharmacy. In an effort to increase transparency, we are pleased to present our 2019 end-of-year report, an analysis of the state of drugs this year.
This report walks through drug price trends in 2019. It highlights medications that made waves, noteworthy government legislation, and medications that saw price increases. It also includes 2020 drug predictions (both good and bad) from our co-CEO, Doug Hirsch.
The report focuses on data from January 1 to October 31, 2019 and includes the following findings:
629 brand and generic drugs increased in price by an average of 8.2%.
Atorvastatin, lisinopril, and levothyroxine were the most prescribed medications of 2019.
Myalept was the most expensive drug in 2019, with a monthly list price of $64,959.
People living in San Francisco paid 17% more than the national average for their medications.
Read the full report here.
Read more like this
Explore these related articles, suggested for readers like you.
Why trust our experts?
